



Note: This document is an English translation of a statement written originally in Japanese. The Japanese original should be considered as the primary version.

February 5, 2026

Company name:	Zeria Pharmaceutical Co., Ltd.
Name of representative:	Mitsuhiro Ibe, Representative Director, President (Securities code: 4559; Prime Market, TSE)
Inquiries:	Koichi Tamura, Director, Public Relations Division (Telephone: +81-3-3661-1039)

Notice regarding Cancellation of Treasury Shares

Zeria Pharmaceutical Co., Ltd. hereby announces that its board of directors resolved at its meeting held on February 5, 2026 to cancel its treasury shares pursuant to Article 178 of the Companies Act of Japan, as follows.

- | | |
|---|--|
| 1. Type of shares to be cancelled | Common shares |
| 2. Total number of shares to be cancelled | 1,000,000 shares
(Equivalent to 1.96% of the issued shares before cancellation) |
| 3. Date of cancellation (planned) | February 25, 2026 |

(Reference)

The total number of issued shares after the cancellation will be 50,119,190 shares.